

PAD Treatment Disparities and Impact on Outcomes of Medicare Beneficiaries

James B. Froehlich, MD, MPH
President, Society for Vascular Medicine

Disclosures

- Consultant: sanofi-aventis; Merck; Boehringer-Ingelheim; Janssen Pharmaceuticals; Johnson & Johnson
- Research Funding: sanofi-aventis; BlueCross/BlueShield of Michigan; FMD Society of America
- I am not a hematologist (no clotting cascades!)
- Off label medication uses WILL be discussed


PAD-Related Amputation Disparities

Age (years)	Black	Nonblack	Relative risk
0–14	0.3	0.3	1.0
15–24	3	1.4	2.1
25–34	11.4	5.1	2.2
35–44	32.2	13.9	2.3
45–54	117.5	41.6	2.8
55–64	268.8	104.6	2.6
65–74	499.5	209.6	2.4
75–84	938.2	312.7	3.0
85+	1355.2	276.8	4.9




PAD-Related Amputation Disparities

Relative Risk of Amputation Black vs. Non-black by Age




PAD-Related Amputation Rate by Race




Amputation and Income

Rates Of Lower-Extremity Diabetic Amputations Per 1,000 Adults Ages Forty-Five And Older With Diabetes, Los Angeles County, 2009




Amputation and Income

Proportion Of Households With Income Below 200 Percent Of The Federal Poverty Level, Los Angeles County, 2003-09




Amputation and Income

Rates Of Lower-Extremity Diabetic Amputations Per 1,000 Adults Ages Forty-Five And Older With Diabetes, Los Angeles County, 2009




Proportion Of Households With Income Below 200 Percent Of The Federal Poverty Level, Los Angeles County, 2003-09



Amputation and Income

Association Between The Low-Income Proportion Of The Population And The Amputation Rate Among Adults In California With Diabetes, 2009



Society for
Vascular Medicine

formerly the Society for Vascular Medicine & Biology (SVM&B)

Health Affairs, 33, no.8 (2014):1383-1390




Disparity in Treatment of PAD Patients: GRACE Study

Management practice	PAD		OR* (95% CI)	
	Present	Absent	Univariable	Multivariable
Procedures (%)				
Cardiac catheterization	49.8	57.6	0.73 (0.69-0.78)	0.89 (0.81-0.97)
PCI/CABG	32.5	40.2	0.72 (0.67-0.77)	0.93 (0.84-1.01)
Medical therapies (inhospital) (%)				
Reperfusion (PCI or thrombolytic therapy)	14.7	26.2	0.49 (0.44-0.54)	0.89 (0.78-1.02)
ACE-I	63.6	62.8	1.03 (0.97-1.11)	0.95 (0.87-1.04)
Aspirin	90.0	93.3	0.65 (0.58-0.72)	0.86 (0.75-0.98)
β-Blocker	75.1	82.9	0.62 (0.58-0.67)	0.75 (0.68-0.83)
Lipid-lowering medications	61.5	61.6	1.00 (0.93-1.06)	0.95 (0.87-1.04)
Warfarin in-hospital	9.8	6.7	1.52 (1.36, 1.71)	1.02 (0.88-1.19)
Smoking counseling (current smokers)	58.6	63.9	0.80 (0.69-0.93)	0.96 (0.80-1.15)
Medical therapies (at discharge) (%)				
ACE-I	59.9	59.1	1.04 (0.96-1.11)	0.92 (0.84-1.01)
Aspirin at discharge	85.8	90.2	0.66 (0.59-0.73)	0.79 (0.70-0.90)
β-Blocker at discharge	68.7	76.5	0.67 (0.62-0.73)	0.73 (0.67-0.81)
Lipid-lowering medications at discharge	63.0	64.0	0.96 (0.89-1.03)	0.90 (0.81-0.99)
Warfarin at discharge	10.4	6.9	1.56 (1.38, 1.76)	1.07 (0.91-1.26)

Disparities in Care of PAD: PVI Registry

	Before PVI, %	After PVI, %
Patients with prior history of CAD or prior peripheral intervention (n=1089)		
Minimal medical therapy	52.5	75.8
Aspirin	88.6	93.3
Statin	80.2	84.5
Smoking abstinence or cessation counseling	69.0	93.4
Patients with no prior history of CAD or prior peripheral intervention (n=261)		
Minimal medical therapy	22.6	51.0
Aspirin	71.3	84.3
Statin	57.9	67.4
Smoking abstinence or cessation counseling	48.3	85.4

Likelihood of Adverse PAD Events: PVI Registry



Disparity in Treatment of PAD: NHANES

	All PAD Subjects (n=647)		PAD Subjects With Recognized CVD (n=196)		PAD Subjects Without CVD (n=451)	
	%	n	%	n	%	n
Statin nonuse	69.5 (2.5)	4 995 332 (179 414)	42.5 (4.2)	929 433 (91 850)	81.7 (2.7)	4 087 147 (135 444)
LDL >100 mg/dL	68.4 (3.8)	4 632 576 (256 021)	62.5 (5.7)	1 366 814 (124 653)	70.7 (4.3)	3 426 456 (209 269)
LDL >70 mg/dL	94.7 (1.4)	6 420 475 (94 200)	89.8 (2.8)	1 963 838 (61 233)	96.7 (1.4)	4 684 998 (65 760)
ACEI/ARB nonuse	75.1 (1.9)	5 395 919 (134 887)	65.6 (3.3)	1 434 608 (72 168)	79.2 (2.2)	3 964 926 (109 609)
SBP \geq 140 mm Hg	45.7 (2.3)	3 246 751 (159 757)	48.9 (3.8)	1 069 395 (83 102)	44.4 (3.0)	2 186 748 (148 910)
Aspirin nonuse	64.2 (2.9)	4 535 159 (206 899)	44.1 (4.1)	964 424 (89 663)	73.0 (3.1)	3 654 114 (153 152)
Not taking any antiplatelet therapy	61.0 (3.2)	4 379 153 (228 488)	34.2 (4.6)	747 920 (100 597)	72.6 (3.1)	3 634 990 (156 014)